Nov 26, 2025 7:00am EST Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Nov 24, 2025 7:00am EST Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
Nov 20, 2025 7:00am EST Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
Nov 18, 2025 7:00am EST Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
Sep 15, 2025 7:00am EDT Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Jul 30, 2025 7:04am EDT Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Jul 28, 2025 7:00am EDT Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Jun 16, 2025 9:00am EDT Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
